In addition, intravenous injection of siRNA-CCR2-NPs to mice decreased monocyte migration to foci of inflammation and thus produced favorable effects in the different models studied: (i) attenuated the number of atherosclerotic plaques, thus reducing the myocardial infarct size after coronary artery occlusion; (ii) prolonged normoglycemia in diabetic mice after pancreatic islet transplantation; and (iii) reduced tumor volume and the number of tumor-associated macrophages in the EL4 lymphoma model; interestingly, TAMs inversely correlates with survival in patients with lymphoma [34]. Here, CCR2 is linked to lymphoma.